Next, we used a tetramer (Tet) to detect CD8+ T cells specific for mutated Adpgk protein (AdpgkMut) in MC38 and shared tumor-associated antigen (TAA), gp70 in CT26 tumors36,37, and found substantially increased frequency of CX3CR1+ Tet+ CD8+ T cells in both tumor models (Fig. 1d), suggesting that T-cell differentiation after ICI therapy occurs in tumor-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.